Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | SCD | O00767 | 4/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15310228 | 0.90 | HSD17B10 (0.49) | L3MBTL1POLBTDP1KLKB1ALDH1A1 | |
| SCHEMBL3092873 | 0.89 | HPGD (0.49) | SCD5POLBKLKB1ALDH1A1LMNA | |
| SCHEMBL3089049 | 0.88 | LMNA (0.50) | CREBBPPOLBKLKB1ALDH1A1HSD17B10 | |
| SCHEMBL3097121 | 0.85 | ALDH1A1 (0.50) | L3MBTL1POLBTDP1ALDH1A1HSD17B10 | |
| SCHEMBL3090463 | 0.85 | ERCC5 (0.46) | L3MBTL1CREBBPALDH1A1ERCC5HDAC1 | |
| SCHEMBL3096925 | 0.84 | TSHR (0.41) | L3MBTL1ALDH1A1LMNA | |
| SCHEMBL3096936 | 0.83 | ALDH1A1 (0.49) | L3MBTL1POLBTDP1ALDH1A1LMNA | |
| SCHEMBL3093669 | 0.81 | TGM2 (0.44) | POLBTDP1ALDH1A1LMNA | |
| SCHEMBL3097709 | 0.78 | KLKB1 (0.45) | L3MBTL1POLBTDP1KLKB1ALDH1A1 | |
| SCHEMBL13153113 | 0.78 | L3MBTL1 (0.56) | L3MBTL1CREBBPSCDSCD5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | L3MBTL1 4273/4885CREBBP 2134/4885SCD 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.